Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 6Thoracic 3Gastrointestinal 3Genitourinary 2Breast 2Sarcoma 1Gynecologic 1CNS 1

Conditions

Prostatic Neoplasms 23Breast Neoplasms 14Neoplasms 7Carcinoma, Ovarian Epithelial 6Testicular Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myeloid, Chronic-Phase 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Fatigue 5Burkitt Lymphoma 5Blast Crisis 5Urinary Bladder Neoplasms 4Primary Myelofibrosis 4Neuroblastoma 4Multiple Myeloma 4Leukemia, Myeloid, Acute 4Leukemia, Hairy Cell 4Depression 4Pdgfra-Associated Chronic Eosinophilic Leukemia 3Myeloproliferative Disorders 3Lymphoma, T-Cell, Cutaneous 3Lung Neoplasms 3

Interventions

pembrolizumab 75Nivolumab 46Cyclophosphamide 25aldesleukin 23fludarabine 16atezolizumab 15Ipilimumab 15Interleukin-2 14Radiosurgery 13Paclitaxel 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Carboplatin 11fludarabine phosphate 9Docetaxel 9durvalumab 8Cisplatin 8cemiplimab 7Bevacizumab 7Radiotherapy 6Gemcitabine 6Biopsy 6spartalizumab 5avelumab 5Pemetrexed 5Oxaliplatin 5Immune Checkpoint Inhibitors 5Filgrastim 5Cryosurgery 5Blood Specimen Collection 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Therapeutics × Genitourinary × Clear all
NCT06180460 2025-10-08

CALM: Managing Distress in Malignant Brain Cancer

Virginia Commonwealth University

Phase NA Completed
60 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡